Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 15, 2026Reported sale · Form 4Joana Goncalves, Chief Medical Officer · $210.8KOpen the filing ↗
- Oct 15, 2026Reported sale · Form 4Joana Goncalves, Chief Medical Officer · $138.0KOpen the filing ↗
- Oct 15, 2026Reported sale · Form 4Joana Goncalves, Chief Medical Officer · $105.7KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record1,33221 flagged findings
Reported transactions (Form 4)80since May 15, 2026 · and 26 other holdings
Corporate events (8-K)30since Dec 9, 2022
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Identity
Formerly traded as ABIO.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-13share offering or dilution eventrecentOpen filing ↗“…6. Accrued Expenses and Other Current Liabilities The following table summarizes accrued expenses and other current liabilities…”
+1 more passage from the same document
- “…for the manufacture of our programs and component materials, developing and progressing our pipeline, and providing general and…”
- 2026-04-29share offering or dilution eventrecentOpen filing ↗“…we will not, without the prior written consent of Leerink Partners LLC, (i) directly or indirectly, offer, pledge, sell,…”
+1 more passage from the same document
- “…lock-up signatories have agreed, with certain limited exceptions, not to directly or indirectly, (i) offer, pledge, sell, contract…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
Reverse splits in 5 years
1 reverse split in 5 years (1:12 on Sep 3, 2024) · 1:12 cumulative
The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).
Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.
The 25 most recent filings (of 1,332)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 15, 26Form 144 ↗Notice of proposed sale new
- Oct 15, 26Form 4 ↗Insider transaction new
- Oct 13, 26Form 144 ↗Notice of proposed sale new
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Oct 1, 26Form 144 ↗Notice of proposed sale
- Sep 21, 26Form 144 ↗Notice of proposed sale
Insider transaction · 7 Form 4 filingsshow all 7hide
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Sep 1, 26Form 144 ↗Notice of proposed sale
- Sep 1, 26Form 144 ↗Notice of proposed sale
- Aug 28, 26424B5 ↗Securities offering
- Aug 25, 26Form 4 ↗Insider transaction
- Aug 25, 26Form 3 ↗Insider transaction
- Aug 24, 268-K ↗Current report · A senior executive left or was appointed
- Aug 21, 26S-3 ↗Securities offering
- Aug 17, 26Form 4 ↗Insider transaction
- Aug 14, 26Form 144 ↗Notice of proposed sale
1,332 filings on record, the oldest from Aug 22, 97.
Listing the 25 most recent filings of the 1,332 on record.
2010875
- Aug 24, 26A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Dec 11, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Sep 22, 25Sold unregistered shares+3 more in the same filing8-K 3.02 ↗
- Jul 1, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Feb 5, 25Entered a material agreement8-K 1.01 ↗
- Dec 19, 24Entered a material agreement8-K 1.01 ↗
- Oct 4, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
4 material agreements entered2024show all 4hide
- Sep 13, 24Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Sep 5, 24Entered a material agreement+11 more in the same filing8-K 1.01 ↗
- Aug 15, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Jul 9, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Apr 23, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 4, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 3, 24Sold unregistered shares+5 more in the same filing8-K 3.02 ↗
- Mar 22, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
6 older filings not shown · The record reaches back to Sep 8, 04.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Apr 22, 19Listing notice (8-K 3.01)8-K 3.01 ↗
- Oct 9, 18Listing notice (8-K 3.01)8-K 3.01 ↗
- Apr 16, 18Listing notice (8-K 3.01)8-K 3.01 ↗
- Jul 16, 15Listing notice (8-K 3.01)8-K 3.01 ↗
- Feb 23, 15Listing notice (8-K 3.01)8-K 3.01 ↗
- May 9, 13Listing notice (8-K 3.01)8-K/A 3.01 ↗
- Mar 25, 13Listing notice (8-K 3.01)8-K 3.01 ↗
- Oct 16, 12Listing notice (8-K 3.01)8-K 3.01 ↗
- Sep 24, 09Restructuring plan with committed costs+3 more in the same filing8-K 2.05 ↗
- Jan 31, 06A debt obligation was accelerated+2 more in the same filing8-K 2.04 ↗
The full record holds 20 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Fairmount Funds Management LLC20.0%Apr 30, 26SCHEDULE 13D/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- Harwin Peter Evan19.5%Jul 1, 26SCHEDULE 13D/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- Venrock Healthcare Capital Partners III, L.P.7.4%Jun 30, 26SCHEDULE 13G/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- BlackRock, Inc.6.6%Dec 31, 25SCHEDULE 13G ↗2 earlier filings
- Capital World Investors5.6%Jun 30, 26SCHEDULE 13G ↗
- RTW Investments, LP5.2%Jun 30, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- The Vanguard Group5.1%Dec 31, 25SCHEDULE 13G ↗
show 2 more holdershide
- Deep Track Capital, LP4.5%Dec 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- VIKING GLOBAL INVESTORS LP2.5%Jun 30, 26SCHEDULE 13G/A ↗10 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Oct 15, JOANA GONCALVES filed notice of intent to sell up to $1.6M. That is about 0.03% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $524K across 5 trades on Oct 15, per their Form 4. That is 33% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+9 more recent notices · 8 with a later sale
- Oct 15, 26Sell$211KJoana GoncalvesChief Medical Officer↗
- Oct 15, 26Sell$138KJoana GoncalvesChief Medical Officer↗
- Oct 15, 26Sell$106KJoana GoncalvesChief Medical Officer↗
- Oct 15, 26Sell$54KJoana GoncalvesChief Medical Officer↗
- Oct 15, 26Sell$16KJoana GoncalvesChief Medical Officer↗
- Oct 12, 26Sell$459KArjun AgarwalSenior Vice President, Finance↗
- Oct 12, 26Sell$170KArjun AgarwalSenior Vice President, Finance↗
- Oct 12, 26Sell$160KArjun AgarwalSenior Vice President, Finance↗
- Oct 12, 26Sell$17KArjun AgarwalSenior Vice President, Finance↗
- Oct 1, 26Sell$1.4MLawrence Otto KleinChief Executive Officer↗
- Oct 1, 26Sell$719KLawrence Otto KleinChief Executive Officer↗
- Oct 1, 26Sell$17KLawrence Otto KleinChief Executive Officer↗
There are 18 more transactions in this stretch.
Stock compensation, tax and giftsshow the 10 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Oct 15, 26Compensation$24KJoana GoncalvesChief Medical Officer↗
- Oct 15, 26Compensation$27KJoana GoncalvesChief Medical Officer↗
- Oct 12, 26Compensation$107KArjun AgarwalSenior Vice President, Finance↗
- Oct 12, 26Compensation$50KArjun AgarwalSenior Vice President, Finance↗
- Oct 1, 26Compensation$195KLawrence Otto KleinChief Executive Officer↗
- Sep 21, 26Compensation$78KPaul T QuinlanGeneral Counsel↗
- Sep 15, 26Compensation$24KJoana GoncalvesChief Medical Officer↗
- Sep 15, 26Compensation$27KJoana GoncalvesChief Medical Officer↗
- Sep 11, 26Compensation$100KArjun AgarwalSenior Vice President, Finance↗
- Sep 11, 26Compensation$50KArjun AgarwalSenior Vice President, Finance↗
The full record holds 195 transactions and goes back to Jan 30, 24.
Its sector and its market
Oruka Therapeutics, Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Oruka Therapeutics, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Oruka Therapeutics, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 1,332 documents on file, from Aug 22, 1997 to Oct 15, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.